Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems

Journal of Psychopharmacology

Volumn 25, Issue 1, 2011, Pages 131-140

  Zarrindast, Mohammad Reza ^a,b,c,d,e   Mahboobi, Sara ^a   Sadat Shirazi, Mitra Sadat ^a   Ahmadi, Shamseddin ^f  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d INSTITUTE FOR STUDIES IN THEORETICAL PHYSICS AND MATHEMATICS IPM   (Iran)

^e INSTITUTE FOR COGNITIVE SCIENCE STUDIES   (Iran)

^f UNIVERSITY OF KURDISTAN   (Iran)

Author keywords

ACPA; anxiety like behaviors; apomorphine; elevated plus maze; SCH23390; sulpiride

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANXIOLYTIC AGENT; APOMORPHINE; ARACHYDONILCYCLOPROPYLAMIDE; CANNABINOID 1 RECEPTOR AGONIST; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; HISTOLOGY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TRANQUILIZING ACTIVITY;

AMYGDALA; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; APOMORPHINE; ARACHIDONIC ACIDS; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; MALE; MOTOR ACTIVITY; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SULPIRIDE;

EID: 78650590575     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110376688     Document Type: Article

References (52)

1. Amaral DG and Corbett BA (2003) The amygdala, autism and anxiety. Novartis Found Symp 251: 177-187.
2. Azad SC, Eder M., Marsicano G., Lutz B., Zieglgansberger W. and Rammes G. (2003) Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10: 116-128.
3. Bartoszyk GD (1998) Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci 62: 649-663.
4. Berrendero F. and Maldonado R. (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 163: 111-117.
5. Brandao ML, Anseloni VZ, Pandossio JE, De Araujo JE and Castilho VM (1999) Neurochemical mechanisms of the defensive behavior in the dorsal midbrain. Neurosci Biobehav Rev 23: 863-875.
6. De la Mora MP, Cardenas-Cachon L., Vazquez-Garcia M., et al. (2005) Anxiolytic effects of intra-amygdaloid injection of the D1 antagonist SCH23390 in the rat. Neurosci Lett 377: 101-105.
7. De Oliveira AR, Reimer AE and Brandao ML (2006) Dopamine D2 receptor mechanisms in the expression of conditioned fear. Pharmacol Biochem Behav 84: 102-111.
8. Domenici MR, Azad SC, Marsicano G., et al. (2006) Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 26: 5794-5799.
9. Furlan SM and Brandao ML (2001) Effects of systemic injections of dopaminergic agents on the habituation of rats submitted to an open field test. Neuropsychobiology 43: 83-90.
10. Garcia AM, Martinez R., Brandao ML and Morato S. (2005) Effects of apomorphine on rat behavior in the elevated plus-maze. Physiol Behav 85: 440-447.
11. Gardner EL (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81: 263-284.
12. Giuffrida A., Parsons LH, Kerr TM, Rodriguez de Fonseca F., Navarro M. and Piomelli D. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363.
13. Hillard CJ, Manna S., Greenberg MJ, et al. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289: 1427-1433.
14. Inoue T., Izumi T., Li XB, Kitaichi Y., Nakagawa S. and Koyama T. (2005) Effect of a dopamine D1/5 receptor antagonist on haloperidol-induced inhibition of the acquisition of conditioned fear. Eur J Pharmacol 519: 253-258.
15. Jaworski JN, Gonzales RA and Randall PK (2001) Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine. Eur J Pharmacol 418: 201-206.
16. Katona I., Rancz EA, Acsady L., et al. (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21: 9506-9518.
17. Laviolette SR and Grace AA (2006) The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 63: 1597-1613.
18. LeDoux JE (2000) Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
19. Li X., Hoffman AF, Peng XQ, Lupica CR, Gardner EL and Xi ZX (2009) Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl) 204: 1-11.
20. Marco EM, Perez-Alvarez L., Borcel E., et al. (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 15: 21-27.
21. Marco EM and Viveros MP (2009) Functional role of the endocannabinoid system in emotional homeostasis. Rev Neurol 48: 20-26.
22. Martin AB, Fernandez-Espejo E., Ferrer B., et al. (2008) Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33: 1667-1679.
23. Micale V., Cristino L., Tamburella A., et al. (2009) Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. Neurobiol Dis 36: 70-80.
24. Moreira FA and Lutz B. (2008) The endocannabinoid system: emotion, learning and addiction. Addict Biol 13: 196-212.
25. O'Neill C., Evers-Donnelly A., Nicholson D., O'Boyle KM and O'Connor JJ (2009) D2 receptor-mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB1 receptors: studies using fast cyclic voltammetry. J Neurochem 108: 545-551.
26. Onaivi ES, Green MR and Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002-1009.
27. Patel S., Cravatt BF and Hillard CJ (2005) Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 30: 497-507.
28. Patel S., Rademacher DJ and Hillard CJ (2003) Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 306: 880-888.
29. Paxinos G. and Watson C. (2006) The rat brain in stereotaxic coordinates, 6 th ed. Amsterdam: Academic Press.
30. Phelps EA and LeDoux JE (2005) Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 48: 175-187.
31. Piomelli D. (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
32. Polissidis A., Chouliara O., Galanopoulos A., et al. (2009) Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol 27: 1-17.
33. Ponnusamy R., Nissim HA and Barad M. (2005) Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn Mem 12: 399-406.
34. Rezayof A., Hosseini SS and Zarrindast MR (2009) Effects of morphine on rat behaviour in the elevated plus maze: the role of central amygdala dopamine receptors. Behav Brain Res 202: 171-178.
35. Rodgers RJ and Johnson NJ (1995) Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 52: 297-303.
36. Rodgers RJ, Nikulina EM and Cole JC (1994) Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav 49: 985-995.
37. Rosenkranz JA and Grace AA (2002) Cellular mechanisms of infra-limbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. J Neurosci 22: 324-337.
38. Rotzinger S. and Vaccarino FJ (2003) Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. J Psychiatry Neurosci 28: 171-181.
39. Rubino T., Guidali C., Vigano D., et al. (2008) CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 54: 151-160.
40. Sah P., Faber ES, Lopez De Armentia M. and Power J. (2003) The amygdaloid complex: anatomy and physiology. Physiol Rev 83: 803-834.
41. Sperlagh B., Windisch K., Ando RD and Sylvester Vizi E (2009) Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. Neurochem Int 54: 452-457.
42. Swanson LW and Petrovich GD (1998) What is the amygdala ? Trends Neurosci 21: 323-331.
43. Talalaenko AN, Abramets IA, Stakhovskii Yu V., Shekhovtsov AA, Chernikov AV and Shevchenko SL (1994) The role of dopaminergic mechanisms on the brain in various models of anxious states. Neurosci Behav Physiol 24: 284-288.
44. Timothy C., Costall B. and Smythe JW (1999) Effects of SCH23390 and raclopride on anxiety-like behavior in rats tested in the black-white box. Pharmacol Biochem Behav 62: 323-327.
45. Troncoso AC, Osaki MY, Mason S., Borelli KG and Brandao ML (2003) Apomorphine enhances conditioned responses induced by aversive stimulation of the inferior colliculus. Neuropsychopharmacology 28: 284-291.
46. Tzavara ET, Wade M. and Nomikos GG (2003) Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 23: 9374-9384.
47. Viveros MP, Marco EM and File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331-342.
48. Zahm DS and Trimble M. (2008) The dopaminergic projection system, basal forebrain macrosystems, and conditioned stimuli. CNS Spectr 13: 32-40.
49. Zarrindast MR, Moghadam AH, Rostami P. and Roohbakhsh A. (2005 a) The effects of histaminergic agents in the central amygdala of rats in the elevated plus-maze test of anxiety. Behav Pharmacol 16: 643-649. (Pubitemid 41682199)
50. Zarrindast MR, Nasehi M., Rostami P., Rezayof A. and Fazli-Tabaei S. (2005 b) Repeated administration of dopaminergic agents in the dorsal hippocampus and morphine-induced place preference. Behav Pharmacol 16: 85-92.
51. Zarrindast MR, Rezayof A., Sahraei H., Haeri-Rohani A. and Rassouli Y. (2003) Involvement of dopamine D1 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat. Brain Res 965: 212-221. (Pubitemid 36183705)
52. Zarrindast MR, Sarahroodi S., Arzi A., Khodayar MJ, Taheri-Shalmani S. and Rezayof A. (2008) Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behaviour: interaction with the opioid system. Behav Pharmacol 19: 716-723.